SPHK1 and cervical carcinoma: Further experimental results showed that SKI-V (3-30 μM) treatment significantly decreased [H3] DNA incorporation (ELISA OD) in pCCa-1 cells (Figure 1D), suggesting that the SphK inhibitor suppressed cervical cancer cell proliferation.